SG10201608904YA - Self-Stabilizing Linker Conjugates - Google Patents
Self-Stabilizing Linker ConjugatesInfo
- Publication number
- SG10201608904YA SG10201608904YA SG10201608904YA SG10201608904YA SG10201608904YA SG 10201608904Y A SG10201608904Y A SG 10201608904YA SG 10201608904Y A SG10201608904Y A SG 10201608904YA SG 10201608904Y A SG10201608904Y A SG 10201608904YA SG 10201608904Y A SG10201608904Y A SG 10201608904YA
- Authority
- SG
- Singapore
- Prior art keywords
- self
- linker conjugates
- stabilizing linker
- stabilizing
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Insulating Materials (AREA)
- External Artificial Organs (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647373P | 2012-05-15 | 2012-05-15 | |
US201361770983P | 2013-02-28 | 2013-02-28 | |
US201361773067P | 2013-03-05 | 2013-03-05 | |
US13/799,244 US9504756B2 (en) | 2012-05-15 | 2013-03-13 | Self-stabilizing linker conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201608904YA true SG10201608904YA (en) | 2016-12-29 |
Family
ID=49584442
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201608904YA SG10201608904YA (en) | 2012-05-15 | 2013-05-14 | Self-Stabilizing Linker Conjugates |
SG11201406252WA SG11201406252WA (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406252WA SG11201406252WA (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2850094B1 (en) |
JP (5) | JP6423340B2 (en) |
KR (5) | KR102144069B1 (en) |
CN (2) | CN108465112B (en) |
AU (5) | AU2013263002C1 (en) |
BR (1) | BR112014028222A2 (en) |
CA (2) | CA2869777C (en) |
EA (1) | EA037203B1 (en) |
HK (1) | HK1207388A1 (en) |
MX (2) | MX368678B (en) |
NZ (3) | NZ741211A (en) |
SG (2) | SG10201608904YA (en) |
WO (1) | WO2013173337A2 (en) |
ZA (1) | ZA201407369B (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013031819B1 (en) | 2011-06-10 | 2022-05-03 | Mersana Therapeutics, Inc | Polymeric support, pharmaceutical composition, compound and support use |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CA2859755C (en) | 2011-12-23 | 2021-04-20 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
NZ741211A (en) * | 2012-05-15 | 2019-09-27 | Seattle Genetics Inc | Self-stabilizing linker conjugates |
MX367851B (en) | 2013-10-11 | 2019-09-09 | Mersana Therapeutics Inc | Protein-polymer-drug conjugates. |
CN105813655B (en) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | Protein-polymer-drug conjugates |
KR102645430B1 (en) | 2013-10-15 | 2024-03-11 | 씨젠 인크. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
JP6701077B2 (en) | 2013-12-19 | 2020-05-27 | シアトル ジェネティックス, インコーポレイテッド | Methylene carbamate linker for use with targeted drug conjugates |
WO2016008112A1 (en) * | 2014-07-16 | 2016-01-21 | Medshine Discovery Inc. | Linkers and application towards adc thereof |
SG11201701311YA (en) * | 2014-09-11 | 2017-03-30 | Seattle Genetics Inc | Targeted delivery of tertiary amine-containing drug substances |
RU2715905C2 (en) * | 2014-10-01 | 2020-03-04 | МЕДИММЬЮН, ЭлЭлСи | Method for conjugation of a polypeptide |
WO2016063959A1 (en) | 2014-10-24 | 2016-04-28 | 日油株式会社 | Antibody-drug complex having cyclic benzylidene acetal linker |
JP6752204B2 (en) * | 2014-12-03 | 2020-09-09 | ジェネンテック, インコーポレイテッド | Quadruple amine compounds and their antibodies-drug conjugates |
CN111620862A (en) * | 2014-12-09 | 2020-09-04 | 艾伯维公司 | BCL-XL-inhibitory compounds and antibody drug conjugates including the same |
RU2020123953A (en) * | 2014-12-09 | 2020-09-18 | Эббви Инк. | BCL-XL INHIBITING COMPOUNDS WITH LOW CELL PERMEABILITY AND ANTIBODY-DRUG CONJUGATES INCLUDING THEM |
SG11201706786UA (en) * | 2015-03-18 | 2017-09-28 | Seattle Genetics Inc | Cd48 antibodies and conjugates thereof |
CN106267225B (en) | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | Trimaleimide-type linker and use thereof |
CN106380508A (en) * | 2015-07-28 | 2017-02-08 | 上海皓元生物医药科技有限公司 | Industrialized production method for antibody coupling medicine connexon |
TWI726942B (en) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | Site specific her2 antibody drug conjugates |
TWI814699B (en) | 2015-12-04 | 2023-09-11 | 美商思進公司 | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
MA43835A (en) | 2016-03-25 | 2018-11-28 | Seattle Genetics Inc | PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINAL PRODUCTS AND THEIR INTERMEDIARIES |
EP3442979A4 (en) * | 2016-04-04 | 2019-12-18 | Rutgers, the State University of New Jersey | Topoisomerase poisons |
WO2017196598A1 (en) * | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugates of tubulysin analogs with enhanced stability |
CN109563168A (en) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | Anti-egfr antibodies drug conjugates |
EP3468615A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
CA3027181A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
CN109562169A (en) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | Anti-CD 98 antibody and antibody drug conjugates |
CA3027046A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
RU2764651C2 (en) | 2016-06-08 | 2022-01-19 | Эббви Инк. | Antibodies to b7-h3 and conjugates of antibody and drug |
CN109641962A (en) | 2016-06-08 | 2019-04-16 | 艾伯维公司 | Anti- B7-H3 antibody and antibody drug conjugates |
EP3468596A2 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
SG11201900699QA (en) * | 2016-08-09 | 2019-02-27 | Seattle Genetics Inc | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
KR20240000650A (en) | 2016-10-19 | 2024-01-02 | 인벤라 인코포레이티드 | Antibody constructs |
JP7244987B2 (en) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | Multidrug Antibody Drug Conjugates |
AU2017383142A1 (en) | 2016-12-22 | 2019-07-04 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43 |
JP2020512312A (en) | 2017-03-24 | 2020-04-23 | シアトル ジェネティックス, インコーポレイテッド | Process for the preparation of glucuronide drug-linker and its intermediates |
CN107652219B (en) * | 2017-08-14 | 2021-06-08 | 上海新理念生物医药科技有限公司 | Tetramaleimide-type linker and application thereof |
BR112020004495A2 (en) | 2017-09-08 | 2020-09-08 | Seattle Genetics, Inc. | compound, composition, and method for preparing a composition. |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
WO2019234136A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
TW202015740A (en) | 2018-06-07 | 2020-05-01 | 美商西雅圖遺傳學公司 | Camptothecin conjugates |
CN113766933A (en) * | 2019-06-28 | 2021-12-07 | 上海复旦张江生物医药股份有限公司 | Antibody coupling drug, intermediate thereof, preparation method and application |
EP4037717A1 (en) | 2019-10-04 | 2022-08-10 | Seagen Inc. | Camptothecin peptide conjugates |
WO2021226454A1 (en) * | 2020-05-08 | 2021-11-11 | Mpeg La, L.L.C. | Linker compounds |
WO2022068898A1 (en) * | 2020-09-29 | 2022-04-07 | 迈威(上海)生物科技股份有限公司 | Preparation method for bis-substituted bridging antibody-drug conjugate |
UY39610A (en) | 2021-01-20 | 2022-08-31 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
TW202320857A (en) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | Linkers, drug linkers and conjugates thereof and methods of using the same |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
WO2023033129A1 (en) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | Pharmaceutical composition for treating and/or preventing cancer |
WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
WO2024092219A1 (en) * | 2022-10-28 | 2024-05-02 | Eli Lilly And Company | Self-hydrolyzing maleimides for bioconjugation |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
JPS63501765A (en) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | Antibody gene module assembly, antibodies produced thereby, and uses |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5091542A (en) * | 1990-03-09 | 1992-02-25 | Hybritech Incorporated | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
WO1994001485A1 (en) * | 1992-07-01 | 1994-01-20 | Akzo Nobel N.V. | Process for the modification of polyphenylene ether resin compositions |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
PT871490E (en) | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | BRIDGED HIDRAZONE LIGANTS |
DE69731289D1 (en) | 1996-03-18 | 2004-11-25 | Univ Texas | IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US5973166A (en) | 1998-03-02 | 1999-10-26 | The Dexter Corporation | Method for the preparation of maleimides |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
EP2357006B1 (en) | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7432331B2 (en) * | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
EP3120861B1 (en) | 2003-11-06 | 2018-08-15 | Seattle Genetics, Inc. | Intermediate for conjugate preparation comprising auristatin derivatives and a linker |
RU2402548C2 (en) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Chemical linkers and conjugates thereof |
CA2564076C (en) | 2004-05-19 | 2014-02-18 | Medarex, Inc. | Chemical linkers and conjugates thereof |
CN102973947A (en) | 2004-06-01 | 2013-03-20 | 健泰科生物技术公司 | Antibody-drug conjugates and methods |
US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
WO2007008603A1 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
EA016577B1 (en) | 2005-09-26 | 2012-06-29 | Медарекс, Инк. | Antibody-drug conjugates and use thereof |
ES2374964T3 (en) | 2006-01-25 | 2012-02-23 | Sanofi | CYTOTOXIC AGENTS UNDERSTANDING NEW TOMAIMYCIN DERIVATIVES. |
CA2702555A1 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
ES2647927T3 (en) | 2008-03-18 | 2017-12-27 | Seattle Genetics, Inc. | Auriestatin drug linker conjugates |
MX2010011807A (en) | 2008-04-30 | 2011-03-04 | Immunogen Inc | Cross-linkers and their uses. |
CN102348723A (en) * | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | Peptide therapeutic conjugates and uses thereof |
WO2010091150A1 (en) | 2009-02-05 | 2010-08-12 | Immunogen, Inc. | Novel benzodiazepine derivatives |
CN102448494B (en) * | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | There is the immune conjugates of the key of cleavable in born of the same parents |
FR2949469A1 (en) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
BR112012026213B1 (en) | 2010-04-15 | 2021-12-28 | Medimmune Limited | PYRROLOBENZODIAZEPINE COMPOUNDS, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION INCLUDING CONJUGATE AND USE THEREOF FOR TREATMENT OF A PROLIFERATIVE DISEASE |
CA2815363C (en) * | 2010-10-22 | 2020-07-14 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
EP3053600B1 (en) | 2011-02-15 | 2020-01-29 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
NZ741211A (en) | 2012-05-15 | 2019-09-27 | Seattle Genetics Inc | Self-stabilizing linker conjugates |
JP2016516035A (en) * | 2013-03-15 | 2016-06-02 | ノバルティス アーゲー | Cell growth inhibitors and their conjugates |
-
2013
- 2013-05-14 NZ NZ74121113A patent/NZ741211A/en unknown
- 2013-05-14 CA CA2869777A patent/CA2869777C/en active Active
- 2013-05-14 BR BR112014028222A patent/BR112014028222A2/en not_active Application Discontinuation
- 2013-05-14 CN CN201810349815.9A patent/CN108465112B/en active Active
- 2013-05-14 EP EP13791383.6A patent/EP2850094B1/en active Active
- 2013-05-14 SG SG10201608904YA patent/SG10201608904YA/en unknown
- 2013-05-14 JP JP2015512756A patent/JP6423340B2/en active Active
- 2013-05-14 EA EA201401254A patent/EA037203B1/en unknown
- 2013-05-14 KR KR1020147034652A patent/KR102144069B1/en active Application Filing
- 2013-05-14 KR KR1020237024059A patent/KR20230113821A/en not_active Application Discontinuation
- 2013-05-14 KR KR1020217023061A patent/KR102475777B1/en active IP Right Grant
- 2013-05-14 KR KR1020227042635A patent/KR102557309B1/en active IP Right Grant
- 2013-05-14 CA CA3131619A patent/CA3131619A1/en not_active Abandoned
- 2013-05-14 SG SG11201406252WA patent/SG11201406252WA/en unknown
- 2013-05-14 MX MX2014013807A patent/MX368678B/en active IP Right Grant
- 2013-05-14 WO PCT/US2013/040951 patent/WO2013173337A2/en active Application Filing
- 2013-05-14 AU AU2013263002A patent/AU2013263002C1/en active Active
- 2013-05-14 NZ NZ724892A patent/NZ724892A/en unknown
- 2013-05-14 KR KR1020207022850A patent/KR102433686B1/en active IP Right Grant
- 2013-05-14 CN CN201380025771.XA patent/CN104822656B/en active Active
- 2013-05-14 NZ NZ630870A patent/NZ630870A/en unknown
-
2014
- 2014-10-10 ZA ZA2014/07369A patent/ZA201407369B/en unknown
- 2014-11-13 MX MX2019012201A patent/MX2019012201A/en unknown
-
2015
- 2015-08-19 HK HK15108030.8A patent/HK1207388A1/en unknown
-
2018
- 2018-02-19 AU AU2018201190A patent/AU2018201190B2/en active Active
- 2018-05-21 JP JP2018097123A patent/JP6709247B2/en active Active
-
2020
- 2020-04-28 AU AU2020202805A patent/AU2020202805B2/en active Active
- 2020-05-22 JP JP2020089453A patent/JP7014856B2/en active Active
-
2021
- 2021-03-16 AU AU2021201636A patent/AU2021201636B2/en active Active
-
2022
- 2022-01-20 JP JP2022007056A patent/JP7431261B2/en active Active
-
2023
- 2023-05-15 AU AU2023203005A patent/AU2023203005A1/en active Pending
-
2024
- 2024-02-01 JP JP2024014096A patent/JP2024032941A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2300020I1 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
HK1207388A1 (en) | Self-stabilizing linker conjugates | |
IL268420A (en) | Oligonucleotide conjugates | |
HRP20180870T1 (en) | Antibody-drug conjugate | |
ZA201502523B (en) | Pyrrolobenzodiazepine-anitbody conjugates | |
ZA201501996B (en) | Drug-protein conjugates | |
IL237672B (en) | Drug-protein conjugates | |
IL233701A0 (en) | Binding molecule conjugates | |
ZA201409119B (en) | Polymer-nsaid conjugate | |
EP2836238A4 (en) | Co-polymer conjugates |